Injectable PLGA Microspheres with LNG
Description: Levonorgestrel (LNG) microspheres encapsulated in PLGA are fabricated to achieve longer duration of hormone release. PLGA with 50:50 and 85:15 lactic acid to glycolic acid copolymer ratios have been studied. An estimated 5 months would be required to deplete the initial drug load with these copolymer ratios.
Product Details
User: Female
Hormonal: Yes
Delivery Method: Injectable
Duration Type: Long-acting
Duration: Five months
Regimen: - single injection
- single injection
Active Pharmaceutical Ingredient (API): - levonorgestrel
- levonorgestrel
Inactive material: PLGA
Multipurpose Preventive Technology (MPT): No
Status Details
Developer: Stanford University
Project Phase: Pre-Clinical and Clinical Development
Development Stage: Pre-clinical
Began discovery in: 2013
Active Development: Unknown
Additional Information
References: Manickam S, et al. (2013) Development and characterization of levonorgestrel-encapsulated injectable poly (lactic-co-glycolic) acid microspheres engineered to specific size distributions for controlled longer-term delivery of contraceptives. Contraception. 88(3): 457-8.
Manickam S, et al. (2013) Development and characterization of levonorgestrel-encapsulated injectable poly (lactic-co-glycolic) acid microspheres engineered to specific size distributions for controlled longer-term delivery of contraceptives. Contraception. 88(3): 457-8.